AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
研究单位：[1]BeiGene[2]First Affiliated Hospital of Kunming Medical University[3]Quanzhou First Hospital of Fujian Province Quanzhou,Fujian,China,362002[4]First Affiliated Hospital of Xiamen University Xiamen,Fujian,China,361003[5]Lanzhou University Second Hospital Gansu,Gansu,China[6]Guangdong Provincial Hospital of Chinese Medicine Guangzhou,Guangdong,China[7]Meizhou Hospital Affiliated to Sun Yat-sen University Guangzhou,Guangdong,China[8]Hainan Third People's Hospital Sanya,Hainan,China[9]Nantong Tumor Hospital Nantong,Jiangsu,China,226000[10]Affiliated Hospital of Jiangnan University Wuxi,Jiangsu,China
研究目的：
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) visually estimated combined positive score (vCPS) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.
